Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feng Bi

Showing results (321-330 of 350) with videos related to

Pageof 35
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 2, 2018
Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trialXin Wang, Yongyang Yu, Wenjian Meng, et al.
Cancer Communications (London, England)|May 26, 2019
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trialYuankai Shi, Jin Li, Jianming Xu, et al.
The Lancet. Oncology|May 19, 2015
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialJin Li, Shukui Qin, Ruihua Xu, et al.
American Journal of Cancer Research|October 12, 2020
Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm studyFeng Wang, Tian-Shu Liu, Xiang-Lin Yuan, et al.
Emerging Microbes & Infections|February 15, 2021
Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune responseChun-Lan Zhuang, Zhi-Jie Lin, Zhao-Feng Bi, et al.
Chinese Journal of Cancer|January 16, 2016
Expert consensus on maintenance treatment for metastatic colorectal cancer in ChinaRui-Hua Xu, Lin Shen, Jin Li, et al.
Hepatology (Baltimore, Md.)|December 17, 2021
Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter studyChun-Yan Wang, Ya Deng, Ping Li, et al.
Journal of Gastroenterology and Hepatology|January 5, 2020
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trialJianming Xu, Rui-Hua Xu, Shukui Qin, et al.
Human Vaccines & Immunotherapeutics|July 14, 2022
Safety and immunogenicity of an <i>Escherichia coli</i>-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trialZhao-Jun Mo, Zhao-Feng Bi, Wei Sheng, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 14, 2024
An optimized short-term steroid therapy for chronic drug-induced liver injury: A prospective randomized clinical trialAng Huang, Yun Zhu, Shuhong Liu, et al.
Pageof 35

Showing results (321-330 of 350) with videos related to

Sort By:
Pageof 35
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 2, 2018
Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trialXin Wang, Yongyang Yu, Wenjian Meng, et al.
Cancer Communications (London, England)|May 26, 2019
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trialYuankai Shi, Jin Li, Jianming Xu, et al.
The Lancet. Oncology|May 19, 2015
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialJin Li, Shukui Qin, Ruihua Xu, et al.
American Journal of Cancer Research|October 12, 2020
Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm studyFeng Wang, Tian-Shu Liu, Xiang-Lin Yuan, et al.
Emerging Microbes & Infections|February 15, 2021
Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune responseChun-Lan Zhuang, Zhi-Jie Lin, Zhao-Feng Bi, et al.
Chinese Journal of Cancer|January 16, 2016
Expert consensus on maintenance treatment for metastatic colorectal cancer in ChinaRui-Hua Xu, Lin Shen, Jin Li, et al.
Hepatology (Baltimore, Md.)|December 17, 2021
Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter studyChun-Yan Wang, Ya Deng, Ping Li, et al.
Journal of Gastroenterology and Hepatology|January 5, 2020
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trialJianming Xu, Rui-Hua Xu, Shukui Qin, et al.
Human Vaccines & Immunotherapeutics|July 14, 2022
Safety and immunogenicity of an <i>Escherichia coli</i>-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trialZhao-Jun Mo, Zhao-Feng Bi, Wei Sheng, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 14, 2024
An optimized short-term steroid therapy for chronic drug-induced liver injury: A prospective randomized clinical trialAng Huang, Yun Zhu, Shuhong Liu, et al.
Pageof 35